Pulse Biosciences, Inc. PLSE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.19M | 751.00K | 350.00K | 86.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.19M | 751.00K | 350.00K | 86.00K | -- |
| Cost of Revenue | 1.18M | 909.00K | 539.00K | 279.00K | -- |
| Gross Profit | 3.00K | -158.00K | -189.00K | -193.00K | -- |
| SG&A Expenses | 31.16M | 30.89M | 32.63M | 34.90M | 32.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.23M | 78.80M | 77.89M | 79.63M | 72.84M |
| Operating Income | -83.04M | -78.05M | -77.54M | -79.55M | -72.84M |
| Income Before Tax | -80.06M | -74.57M | -72.78M | -74.73M | -68.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.06 | -74.57 | -72.78 | -74.73 | -68.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.06M | -74.57M | -72.78M | -74.73M | -68.03M |
| EBIT | -83.04M | -78.05M | -77.54M | -79.55M | -72.84M |
| EBITDA | -82.02M | -77.00M | -76.47M | -78.45M | -71.70M |
| EPS Basic | -1.17 | -1.10 | -1.08 | -1.14 | -1.06 |
| Normalized Basic EPS | -0.73 | -0.69 | -0.68 | -0.72 | -0.67 |
| EPS Diluted | -1.17 | -1.10 | -1.08 | -1.14 | -1.06 |
| Normalized Diluted EPS | -0.73 | -0.69 | -0.68 | -0.72 | -0.67 |
| Average Basic Shares Outstanding | 272.37M | 270.44M | 269.58M | 263.84M | 257.52M |
| Average Diluted Shares Outstanding | 272.37M | 270.44M | 269.58M | 263.84M | 257.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |